India, Oct. 9 -- This week, biopharmaceutical companies saw a busy week of regulatory decisions, strategic partnerships and clinical developments, alongside pipeline setbacks and workforce reductions.
Roche, Novartis, Pfizer, and Eli Lilly reported regulatory milestones, while GE HealthCare announced the acquisition of SOFIE Biosciences. Meanwhile, Caribou Biosciences outlined restructuring plans and program halts amid financial priorities.
On the clinical front, Argenx, AbbVie, Genmab, BridgeBio and Vaxcyte highlighted progress across immunology, oncology, rare diseases and vaccines.
Let us unpack the specifics.
Regulatory Approvals
Roche's Tecentriq Regimen Approved for Stage III dMMR Colon CancerRoche Holding AG (RHHBY) received U.S...